Ascendis Pharma A/S (NASDAQ:ASND) Posts Quarterly Earnings Results, Misses Estimates By $0.68 EPS

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68), FiscalAI reports. The firm had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 246.61% and a net margin of 70.99%.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• Q2 revenue more than doubled year over year to €339 million, including €315 million of product revenue and a €17 million TransCon CNP milestone. Management also reported €207 million of net profit and €812 million in cash and cash equivalents.
• YORVIPATH demand remained robust, with approximately 1,000 new U.S. patient enrollments per quarter and availability commercially or through named-patient programs in more than 35 countries. Long-term data showed sustained efficacy, quality-of-life improvements, and patient retention of up to 95% after five years.
• YUVIWEL uptake is accelerating, with more than 220 U.S. enrollments and over 65% approved for reimbursement by the end of July. Management believes the product is expanding the achondroplasia treatment market and could become the leading therapy, supported by planned global launches and a phase III combination trial with TransCon growth hormone.
• Management reiterated confidence in its long-term growth targets, including more than €500 million of operating cash flow in 2026 and €5 billion of revenue by 2030, while expecting increased operating leverage as launches scale.
• YUVIWEL remains subject to an ongoing U.S. intellectual-property dispute with BioMarin, with an initial ITC opinion expected in August, a broader ITC decision in December, and a potential presidential review thereafter. Management expects no material impact, but the legal process remains a source of uncertainty.

Ascendis Pharma A/S Trading Up 0.9%

Shares of ASND stock opened at $248.50 on Friday. Ascendis Pharma A/S has a 1-year low of $186.05 and a 1-year high of $282.15. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The stock has a market cap of $15.50 billion, a price-to-earnings ratio of 19.28 and a beta of 0.39. The stock has a 50-day moving average of $249.60 and a 200-day moving average of $237.24.

Insider Activity at Ascendis Pharma A/S

In related news, Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average cost of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the acquisition, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 40.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently modified their holdings of ASND. HRT Financial LP bought a new position in Ascendis Pharma A/S during the fourth quarter worth $239,000. PharVision Advisers LLC acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $233,000. Graham Capital Management L.P. bought a new position in shares of Ascendis Pharma A/S in the 4th quarter worth about $228,000. Certuity LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $220,000. Finally, SummitTX Capital L.P. acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $207,000.

Analysts Set New Price Targets

Several brokerages recently issued reports on ASND. Jefferies Financial Group reaffirmed a “buy” rating and set a $333.00 price target on shares of Ascendis Pharma A/S in a report on Thursday. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday. Morgan Stanley boosted their price objective on Ascendis Pharma A/S from $256.00 to $275.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings upgraded Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, Oppenheimer restated an “outperform” rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $299.24.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.